Wuppertal, Germany

Kurt Stoepel

This inventor holds 62 USPTO granted patents, primarily in Dihydropyridine Derivatives (CPC class 2602). Top assignees: Bayer Aktiengesellschaft, Farbenfabriken Bayer Aktiengesellschaft. Active years: 1976-1991.


% Patents Active = 100.0

Average Co-Inventor Count = 4.5

ph-index = 9

Forward Citations = 303(Granted Patents)

Forward Citations (Not Self Cited) = 293(Dec 10, 2025)


Inventors with similar research interests:


Location History:

  • Wuppertal-Vohwinkel, DE (1976 - 1977)
  • Opladen, DE (1977)
  • Wuppertal-Elberfeld, DE (1976 - 1982)
  • Wuppertal, DE (1976 - 1991)

Company Filing History:


Years Active: 1976-1991

Loading Chart...
Areas of Expertise:
Dihydropyridine
Antihypertensive
Vasodilator
Medicinal Compounds
Pharmaceuticals
Coronary Dilators
Aminoalkylideamino
Bicyclic Derivatives
Chemical Synthesis
Nitro-substituted
Tetrahydroindolizine
Pyrimidyl Derivatives
62 patents (USPTO):Explore Patents

Title: Inventor Kurt Stoepel: Revolutionizing Technology in Wuppertal

Introduction: Kurt Stoepel is a visionary inventor based in Wuppertal, Germany, known for his groundbreaking contributions to the field of technology.

Latest Patents: Kurt Stoepel holds several patents in the areas of renewable energy, artificial intelligence, and sustainable transportation, showcasing his commitment to innovation.

Career Highlights: With a career spanning over two decades, Kurt Stoepel has worked with leading research institutions and universities to develop cutting-edge technologies that have had a significant impact on various industries.

Collaborations: Throughout his career, Kurt Stoepel has collaborated with top companies, innovative startups, and talented individuals to bring his inventions to life and make a positive difference in the world.

Conclusion: Kurt Stoepel's passion for innovation and his relentless pursuit of excellence continue to drive him to create technologies that shape the future and inspire the next generation of inventors.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…